BetterLife Pharma Inc.
BETR
CNSX
| 04/30/2026 | 01/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 41.38% | 2.65% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 27.34% | 14.87% | |||
| Operating Income | -27.34% | -14.87% | |||
| Income Before Tax | -59.19% | 7.10% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -59.19% | 7.10% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 212.50% | -90.00% | |||
| Net Income | -58.70% | 4.82% | |||
| EBIT | -27.34% | -14.87% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -52.63% | 0.00% | |||
| Normalized Basic EPS | -58.33% | 0.00% | |||
| EPS Diluted | -52.63% | 13.64% | |||
| Normalized Diluted EPS | -58.33% | 0.00% | |||
| Average Basic Shares Outstanding | 1.93% | -0.24% | |||
| Average Diluted Shares Outstanding | 1.93% | -0.24% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||